Using Serological Proteome Analysis to Identify and Evaluate Anti-GRP78 Autoantibody as Biomarker in the Detection of Gastric Cancer

Table 1

The basic characteristics of the participants.

Factors	Subgroup	Test group		Validation group
		GC (N = 133)	NH (N = 133)	GC (N = 300)	NH (N = 300)
Age
	Range	31–94	31–89	23–89	23–88
	Median	61	61	59	59
	IQR	15	16	19	18
Gender
	Male	92 (69.2%)	92 (69.2%)	226 (75.3%)	226 (75.3%)
	Female	41 (30.8%)	41 (30.8%)	74 (24.7%)	74 (24.7%)
TNM
	I	16 (12.0%)		55 (18.3%)
	II	21 (15.8%)		60 (20.0%)
	III	53 (39.8%)		85 (28.3%)
	IV	14 (10.5%)		29 (9.7%)
	Unknown	29 (21.8%)		71 (23.7%)
Tumor size
	<5 cm	48 (36.1%)		77 (25.7%)
	≥5 cm	36 (27.1%)		71 (23.7%)
	Unknown	49 (36.8%)		152 (50.7%)
Lymphatic metastasis
	Yes	68 (51.1%)		138 (46.0%)
	No	33 (24.8%)		83 (27.7%)
	Unknown	32 (24.1%)		79 (26.3%)
Differentiation degree
	Poor	52 (39.1%)		104 (34.6%)
	Moderate	47 (35.3%)		112 (37.3%)
	High	0 (0.0%)		5 (1.7%)
	Unknown	34 (25.6%)		36 (25.4%)

GC: gastric cancer; NH: normal human.